REG - Proteome Sciences - Notice of Results

Proteome SciencesAnnouncement

29/03/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220329:nRSc3096Ga&default-theme=true

RNS Number : 3096G  Proteome Sciences PLC  29 March 2022

 

 

 
 
29 March 2022

 

 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

 

Notice of Results

 

The Directors of Proteome Sciences look forward to updating shareholders on
the Company's performance, and on the outlook for 2022, at the time of
announcing the 2021 full year results which are scheduled for announcement on
Thursday, 31 March 2022.

 

 

For further information please contact:

 

 Proteome Sciences plc

 Dr Mariola Soehngen, Chief Executive Officer  Tel: +44 (0)20 7043 2116
 Dr Ian Pike Chief Scientific Officer

 Richard Dennis, Chief Commercial Officer

 Allenby Capital Limited (AIM Nominated Adviser & Broker)
 John Depasquale / Jeremy Porter               Tel: +44 (0) 20 3328 5656

 

About Proteome Sciences plc. (www.proteomics.com (http://www.proteomics.com/)
)

 

Proteome Sciences plc is a specialist provider of contract proteomics services
to enable drug discovery, development and biomarker identification, and
employs proprietary workflows for the optimum analysis of tissues, cells and
body fluids.  SysQuant® and TMT®MS2 are unbiased methods for identifying
and contextualising new targets and defining mechanisms of biological
activity, while analysis using Super-Depletion and TMTcalibrator™ provides
access to over 8,500 circulating plasma proteins for the discovery of
disease-related biomarkers. Targeted assay development using mass spectrometry
delivers high sensitivity, interference-free biomarker analyses in situations
where standard ELISA assays are not available.

 

The Company has its headquarters in London, UK, with laboratory facilities in
Frankfurt, Germany.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORKVLFLLXLXBBE